Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-blind study of inhaled ASM8 in adults with moderate to severe asthma
2011-000126-30Phase 2Terminated
- Sponsor
- Pharmaxis
- Start
- May 2011
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in asthma comparing ASM8 inhalation arm with Placebo inhalation arm (2 arms). Primary endpoint: Safety and tolerability of ASM8. Started May 2011; status: terminated.
02
Drugs
ASM8
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-000126-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000126-30.